Efficacy of dosimetric versus empiric prescribed activity of 131I for therapy of differentiated thyroid cancer

Joanna Klubo-Gwiezdzinska, Douglas Van Nostrand, Frank Atkins, Kenneth Burman, Jacqueline Jonklaas, Mihriye Mete, Leonard Wartofsky, Joanna Klubo-Gwiezdzinska, Douglas Van Nostrand, Frank Atkins, Kenneth Burman, Jacqueline Jonklaas, Mihriye Mete, Leonard Wartofsky

Abstract

Background: The optimal management of high-risk patients with differentiated thyroid cancer (DTC) consists of thyroidectomy followed by radioiodine ((131)I) therapy. The prescribed activity of (131)I can be determined using two approaches: 1) empiric prescribed activity of (131)I (E-Rx); and 2) dosimetry-based prescribed activity of (131)I (D-Rx).

Aim: The aim of the study was to compare the relative treatment efficacy and side effects of D-Rx vs. E-Rx.

Methods: A retrospective analysis was performed of patients with distant metastases and/or locoregionally advanced radioiodine-avid DTC who were treated with either D-Rx or E-Rx. Response to treatment was based on RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria.

Results: The study group consisted of 87 patients followed for 51 ± 35 months, of whom 43 were treated with D-Rx and 44 with E-Rx. Multivariate analysis, controlling for age, gender, and status of metastases revealed that the D-Rx group tended to be 70% less likely to progress (odds ratio, 0.29; 95% confidence interval, 0.087-1.02; P = 0.052) and more likely to obtain complete response (CR) compared to the E-Rx group (odds ratio, 8.2; 95% confidence interval, 1.2-53.5; P = 0.029). There was an association in the D-Rx group between the observed CR and percentage of maximum tolerable activity given as a first treatment of (131)I (P = 0.030). The advantage of D-Rx was specifically apparent in the locoregionally advanced group because CR was significantly higher in D-Rx vs. E-Rx in this group of patients (35.7 vs. 3.3%; P = 0.009). The rates of partial response, stable disease, and progression-free survival, as well as the frequency of side effects, were not significantly different between the two groups.

Conclusion: Higher efficacy of D-Rx with a similar safety profile compared to E-Rx supports the rationale for employing individually prescribed activity in high-risk patients with DTC.

Figures

Fig. 1
Fig. 1
Objective response to the treatment with 131I. A, Whole study group. Kaplan-Meier curves of PFS for patients treated with D-Rx vs. E-Rx (P = 0.34). B and C, Patients with DM. B, No statistically significant differences in the treatment efficacy in patients with DM treated with D-Rx vs. E-Rx [CR, two of 29 (6.9%) vs. one of 14 (7.1%), P = 0.704; PR, 0 of 29 vs. 0 of 14, P = 1.0; SD, 21 of 29 (72.4%) vs. eight of 14 (57.2%), P = 0.202; and PD, six of 29 (20.7%) vs. five of 14 (35.7%), P = 0.244]. C, No differences in PFS in the DM group treated with D-Rx vs. E-Rx (P = 0.61). D and E, Patients with LA disease. D, Higher rate of CR in D-Rx group compared with E-Rx [five of 14 (35.7%) vs. one of 30 (3.3%); P = 0.009]. No differences in PR, SD, PD [PR, 0 of 14 (0%) vs. 0 of 30 (0%), P = 1.0; SD, eight of 14 (57.2%) vs. 23 of 30 (76.7%), P = 0.951; PD, one of 14 (7.1%) vs. six of 30 (20.0%), P = 0.270]. E, No difference in PFS in the LA group of patients treated with D-Rx vs. E-Rx (P = 0.422). DM, Distant metastases; LA, locally advanced.
Fig. 2
Fig. 2
No difference in the frequency of adverse side effects in patients treated with D-Rx vs. E-Rx. PLT, Platelets; RPD, restrictive pulmonary disease.

References

    1. Jemal A , Siegel R , Xu J , Ward E. 2010. Cancer statistics 2010. CA Cancer J Clin 60:277–300
    1. Davies L , Welch HG. 2006. Increasing incidence of thyroid cancer in the United States, 1988–2005. JAMA 295:2164–2167
    1. Ries LA , Eisner MP , Kosary CL. 2006. SEER cancer statistics review, 1975–2000/2003. Bethesda, MD: National Cancer Institute;
    1. Chen AY , Jemal A , Ward EM. 2009. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer 115:3801–3807
    1. Rego-Iraeta A , Pérez-Méndez LF , Mantinan B , Garcia-Mayor RV. 2009. Time trends for thyroid cancer in northwestern Spain: true rise in the incidence of micro and larger forms of papillary thyroid cancer. Thyroid 19:333–340
    1. Enewold L , Zhu K , Ron E , Marrogi AJ , Stojadinovic A , Peoples GE , Devesa SS. 2009. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev 18:784–791
    1. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS , Doherty GM , Haugen BR , Kloos RT , Lee SL , Mandel SJ , Mazzaferri EL , McIver B , Pacini F , Schlumberger M , Sherman SI , Steward DL , Tuttle RM. 2009Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214
    1. Van Nostrand D , Atkins F , Yeganeh F , Acio E , Bursaw R , Wartofsky L. 2002. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid 12:121–134
    1. Kulkarni K , Van Nostrand D , Atkins F , Aiken M , Burman K , Wartofsky L. 2006. The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. Thyroid 16:1019–1023
    1. Tuttle RM , Leboeuf R , Robbins RJ , Qualey R , Pentlow K , Larson SM , Chan CY. 2006. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 47:1587–1591
    1. Benua RS , Cicale NR , Sonenberg M , Rawson RW. 1962. The relation of radioiodine dosimetry to results and side effects in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med 87:171–182
    1. Samuel AM , Rajashekharrao B , Shah DH. 1998. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med 39:1531–1536
    1. Lassmann M , Reiners C , Luster M. 2010. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer 17:R161–R172
    1. Eisenhauer EA , Therasse P , Bogaerts J , Schwartz LH , Sargent D , Ford R , Dancey J , Arbuck S , Gwyther S , Mooney M , Rubinstein L , Shankar L , Dodd L , Kaplan R , Lacombe D , Verweij J. 2009. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247
    1. Van Nostrand D , Freitas J. 2006. Side effects of 131-I for ablation and treatment of well differentiated thyroid carcinoma. In: , Wartofsky L , Van Nostrand D eds. Thyroid cancer: a comprehensive guide to clinical management. 2nd ed Totowa, NJ: Humana Press; 459–485
    1. Sgouros G , Song H , Ladenson PW , Wahl RL. 2006. Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med 47:1977–1984
    1. Benua RS , Leeper RD. 1986. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of I-131. In: , Medeiros-Neto G , Gaitan E eds. Frontiers in thyroidology. Vol. 2 New York: Plenum Medical Book Co.; 1317–1321
    1. Verburg FA , Hänscheid H , Biko J , Hategan MC , Lassmann M , Kreissl MC , Reiners C , Luster M. 2010. Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience. Eur J Nucl Med Mol Imaging 37:896–903
    1. Lassmann M , Hänscheid H , Chiesa C , Hindorf C , Flux G , Luster M, EANM Dosimetry Committee 2008EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging 35:1405–1412
    1. Lee JJ , Chung JK , Kim SE , Kang WJ , Park do J , Lee DS , Cho BY , Lee MC. 2008. Maximal safe dose of I-131 after failure of standard fixed dose therapy in patients with differentiated thyroid carcinoma. Ann Nucl Med 22:727–734
    1. Thomas SR , Maxon HR , Kereiakes JG. 1976. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys 3:253–255
    1. Dorn R , Kopp J , Vogt H , Heidenreich P , Carroll RG , Gulec SA. 2003. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med 44:451–456
    1. Schlumberger M , Challeton C , De Vathaire F , Travagli JP , Gardet P , Lumbroso JD , Francese C , Fontaine F , Ricard M , Parmentier C. 1996. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598–605

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa